TNF and histiocytic sarcoma: Moreover, Balato et al. [39] analyzed, on HS patients, the effects of adalimumab, the only TNF-α antagonist approved by Food and Drug Administration (FDA) and EMA (European Medicines Agency) for moderate-to-severe HS, on mTORC1 (mTOR Complex 1) activity, highlighting both the specific involvement of mTORC1 in HS pathogenesis and its potential prominent role as possible new mechanism by which TNF-α inhibition improves HS.